Clinical Trials Office

罗林斯癌症中心(HCC)临床试验办公室(CTO)为南卡罗来纳医科大学(MUSC)的癌症临床试验提供了一个中央办公室。肝细胞癌CTO的目的是提供有效和高效的临床研究基础设施，以支持研究人员和临床医生开发和实施临床研究研究。首席技术官的主要职能是： 协助中心首席调查员启动和管理研究，包括科学、伦理、财务和业务审查所需的准备和沟通，以及对年度监管审查的持续支持 协助临床医生筛选和招募参加临床研究的患者 协调并确保完成针对患者的研究要求 为临床研究提供数据管理支持为内部和外部质量和合规性审计准备医疗和研究记录向临床和CTO工作人员以及新调查人员提供与进行临床研究的最佳实践有关的培训和教育，向肝细胞癌医生、转介医生和公众管理肝细胞癌临床试验网络，该网络促进全州临床试验的获得在过去十年中，肝细胞癌扩大了其能力、服务和能力，并被认为是 MUSC最有效和最高效的临床研究单位。目前，肝细胞癌首席技术官为21个MUSC部门/部门提供服务，临床试验组合包括来自所有主要NCI合作小组试验(例如，SWOG、RTOG、GOG、COG、ACRIN、ACOSOG、NSABP)的研究、行业赞助研究和越来越多的研究人员发起的研究。治疗性临床试验的收益在过去五年中翻了两番，现在占新发肝癌病例总数的11%。

The Rollings Cancer Center (HCC) Clinical Trials Office (CTO) provides a centralized office for the conduct of cancer clinical trials at the Medical University of South Carolina (MUSC). The purpose of the HCC CTO is to provide an effective and efficient clinical research infrastructure to support investigators and clinicians in developing and implementing clinical research studies. The major functions of the CTO are to: Assist HCC Principal Investigators in the activation and administration of studies, including the preparations and communications required for scientific, ethical, financial and operational reviews as well as ongoing support for annual regulatory reviews Assist clinicians in screening and enrolling patients for clinical research studies Coordinate and ensure the completion of patient-specific study requirements Provide data management support for clinical research studies Prepare medical and research records for internal and external quality and compliance audits Provide training and education pertaining to the best practices in conducting clinical studies to clinical and CTO staff as well as new investigators Communicate the availability of clinical studies to HCC physicians, referring physicians and the public Administer the HCC Clinical Trials Network, which promotes statewide clinical trial access Over the past decade the CTO has expanded its capacity, services and capabilities and is considered one of MUSC's most effective and efficient clinical research units. Currently, the HCC CTO provides services to twenty-one MUSC departments/divisions and the clinical trials portfolio includes studies from all of the major NCI Cooperative Group trials (e.g., SWOG, RTOG, GOG, COG, ACRIN, ACoSOG, NSABP), industry sponsored studies and a growing number of investigator-initiated studies. Accrual to therapeutic clinical trials has quadrupled during the past five years and now represents 11% of total new HCC cancer cases.